Phase 2, BDTX-1535 and Black Diamond
Black Diamond reports encouraging Phase 2 data for BDTX-1535
Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment of patients with recurrent EGFR-mutant non-small cell lung cancer, or NSCLC.
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment
Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLC
Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or
Black Diamond Therapeutics Inc (BDTX) Stock’s 0.98% Increase This Year: What’s the Story?
Raymond James has recently initiated Black Diamond Therapeutics Inc (BDTX) stock to Outperform rating, as announced on July 31, 2024, according to Finviz. Earlier, on July 14, 2023, Piper Sandler had initiated the stock to Overweight.
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday,
Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The
FierceBiotech3d
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...
GearJunkie on MSN13h
The Moves Should Be Hard, Not the Approach: Black Diamond Erratic Bouldering Crash Pad Review
Black Diamond's new Erratic bouldering crash pad is lighter and has a more substantial carrying system than others. The post ...
Business Insider9d
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Black Diamond Therapeutics (BDTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating ...
The Post5h
Athens Ohio Roller Derby prepares for Back to School Bash
Athens Ohio Roller Derby Team plans to hold its Back to School Bash doubleheader, with discounts for educators and free entry ...
Enumclaw Courier-Herald on MSN9d
Oakpointe’s developments are 20% completed. What’s next? Recreation
Ten Trails and Lawson Hills neighborhoods developer Oakpointe is asking the Black Diamond City Council to consider recreation ...
The Roanoke Times1d
Bowl projections for Hokies after Week 4: Black Diamond Trophy on the line in Tampa?
BLACKSBURG —A bunch of Virginia Tech and West Virginia fans converge in Tampa before Christmas. What could go wrong?
Trump Launches Line of Watches, Including a $100,000 ‘Victory Tourbillon’
The former president has sold branded sneakers, Bibles, NFTs, and coffee table books. Now he’s moving into timepieces ...
Vienna-Goreville Football will no longer play in Black Diamond Conference
Goreville Football will no longer participate in the Black Diamond Conference. This comes after a vote by the BDC that was ...